MorphoSys AG (NASDAQ:MOR) Receives Consensus Recommendation of "Hold" from Analysts

Shares of MorphoSys AG (NASDAQ:MOR - Get Free Report) have been assigned a consensus rating of "Hold" from the eight brokerages that are covering the company, Marketbeat reports. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $11.78.

A number of analysts recently issued reports on the company. Wells Fargo & Company restated an "equal weight" rating and issued a $18.25 price target (up from $17.00) on shares of MorphoSys in a research report on Thursday, March 14th. Morgan Stanley reiterated an "equal weight" rating on shares of MorphoSys in a research report on Friday, January 19th.

Hedge Funds Weigh In On MorphoSys

Hedge funds and other institutional investors have recently modified their holdings of the business. Quadrant Capital Group LLC lifted its holdings in MorphoSys by 204.8% during the fourth quarter. Quadrant Capital Group LLC now owns 5,572 shares of the company's stock worth $55,000 after buying an additional 3,744 shares during the period. Exchange Traded Concepts LLC boosted its position in MorphoSys by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 17,437 shares of the company's stock valued at $173,000 after purchasing an additional 4,421 shares in the last quarter. Virtu Financial LLC purchased a new position in MorphoSys in the fourth quarter valued at about $244,000. Henry James International Management Inc. bought a new position in MorphoSys in the fourth quarter worth about $426,000. Finally, SAL Trading LLC purchased a new stake in shares of MorphoSys during the first quarter valued at about $486,000. 18.38% of the stock is currently owned by institutional investors.

MorphoSys Trading Up 0.6 %

MOR traded up $0.11 during trading on Wednesday, reaching $18.50. The company had a trading volume of 259,134 shares, compared to its average volume of 1,561,592. The stock has a market cap of $2.79 billion, a P/E ratio of -5.32 and a beta of 1.15. The business has a 50 day simple moving average of $18.01 and a 200-day simple moving average of $13.25. MorphoSys has a 52 week low of $4.18 and a 52 week high of $18.59. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 4.98.

MorphoSys (NASDAQ:MOR - Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $1.25. The company had revenue of $63.53 million during the quarter, compared to the consensus estimate of $76.30 million. MorphoSys had a negative return on equity of 694.31% and a negative net margin of 226.79%. On average, equities analysts anticipate that MorphoSys will post -2.08 EPS for the current fiscal year.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.